Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy

• Main Author: Joseph Martin Alisky
• Format: Article
• Language: English
• Published: IJCTO 2014-02-01
• Series: International Journal of Cancer Therapy and Oncology
• Subjects: Interleukin-2; Cytokines; Treatment Protocols
• Online Access: http://ijcto.org/index.php/IJCTO/article/view/80

<p>Treatment of stave IV renal cell cancer and melanoma with intravenous interleukin-2 (IL-2) is often limited by side effects, and only a minority of patients obtain sustained remissions. This editorial proposes that infusing IL-2 into the splenic artery will allow much stronger immune activation without systemic side effects, achieving a superior clinical response and enabling treatment of patients currently excluded from IL-2 by medical comorbidities.</p><p>----------------------------------</p><p><strong>Cite this article as</strong>: Alisky JM. Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(1):020115.</p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0201.15" target="_blank">http://dx.doi.org/10.14319/ijcto.0201.15</a></p><p> </p>